Phosphatases in Systemic Autoimmunity
Phosphatases in Systemic Autoimmunity
批准号:
10468134
负责人:
George C Tsokos
金额:
$43.75万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-18 至 2024-08-31
关键词:
AddressAutoimmune DiseasesAutoimmune ResponsesAutoimmunityBindingCell DeathCell physiologyCellsClinical TrialsDataDiseaseDoseEnzymesEtiologyFunctional disorderGenerationsGenesGenetic TranscriptionGlomerulonephritisHumanIL17 geneImmuneImmunosuppressive AgentsInfectionInflammationInterleukin-17Interleukin-2InterleukinsLupusMediatingMessenger RNAMolecularMorbidity - disease rateMusOpportunistic InfectionsPathogenesisPathologyPathway interactionsPatientsPeripheralPhosphoric Monoester HydrolasesProductionProtein Serine/Threonine PhosphataseProtein phosphataseProteinsRegulationRegulatory T-LymphocyteRoleSP1 geneSerumSignal PathwaySiteSpecificitySurfaceSusceptibility GeneSystemic Lupus ErythematosusT-LymphocyteT-Lymphocyte SubsetsTestingTissuesWorkautoreactive T cellcytotoxicdeprivationdesigneffector T cellexperimental studyimmune functionimmunopathologyinfection ratelupus prone micemortalitynephrogenesisnoveloverexpressionprotein phosphatase 2A regulatory subunit 65 kDaresponsescaffoldsystemic autoimmunitytooltranscription factor
中文摘要
摘要
好了!
系统性红斑狼疮(SLE)表现为严重的T细胞效应器功能障碍。白介素2
(IL-2)缺乏是感染相关发病率和死亡率增加的原因,
调节细胞(Treg)功能缺陷和消除自身反应性T的能力受损
细胞。同时,T细胞产生更多的白介素17(IL-17),这与
在组织炎症和损伤方面。蛋白磷酸酶2A(PP2A)是第一个丝氨酸/苏氨酸
磷酸酶首先对人类系统性红斑狼疮起作用,后来对小鼠狼疮起作用
免疫病理学。它是一种由支架、催化和调节组成的三分子酶。
亚单位。我们已经证明,PP2Ac在SLE患者中的表达增加,而且确实如此
许多信号通路的中心,包括抑制IL-2的产生
并增强IL-17的产生,以及调节B亚单位β调节IL-17
2剥夺诱导T细胞死亡,SLE患者T细胞死亡减少。缺乏PP2A的小鼠
Tregs会发展成严重的炎症和自身免疫,因为PP2Ac是
抑制mTORC1通路。利用新的小鼠和分子工具,提出了
这项工作将检验PP2Ac代表着
系统性红斑狼疮和自身免疫的免疫发病机制:1)确定
PP2A在Tregs中的表达在调节自身免疫反应及相关病理中的作用;
2)确定PP2A在常规T细胞中的表达在调节
自身免疫反应和相关病理;3)建立异常表达
在人类系统性红斑狼疮中调节B亚单位α,并确定它如何对IL-17的产生起作用。
该项目将产生新的概念(通过以下方式对中枢免疫功能进行差异调节
PP2A,通过特定的调节亚基调节不同的功能)和新的信息小鼠
(T细胞亚群中缺乏PP2A的小鼠和T细胞中缺乏调节亚基的小鼠)。
理解系统性基因表达的分子复杂性
如果我们希望纠正治疗患者的重要途径,自身免疫是非常重要的。
在老鼠和人类身上进行平行研究的能力显著增加了
我们工作的翻译价值。
好了!
好了!
好了!
英文摘要
Abstract
!
Systemic lupus erythematosus (SLE) presents profound T cell effector dysfunction. Interleukin-2
(IL-2) deficiency accounts for the increased infection-related morbidity and mortality rates, the
defective regulatory cell (Treg) function and compromised ability to eliminate autoreactive T
cells. In parallel, T cells produce increased amounts of interleukin-17 (IL-17) which is involved
in tissue inflammation and damage. Protein phosphatase 2A (PP2A) is the first serine/threonine
phosphatase recognized to contribute first to human SLE and later to murine lupus
immunopathology. It is a trimolecular enzyme consisting of scaffolding, catalytic and regulatory
subunits. We have shown that PP2Ac expression is increased in patients with SLE and that it is
central to a number of signaling pathways including the suppression of the production of IL-2
and the enhancement of the production of IL-17 and that the regulatory subunit Bβ regulates IL-
2 deprivation-induced T cell death and is decreased in SLE patients. A mouse lacking PP2A in
Tregs develops severe inflammation and autoimmunity because PP2Ac is needed for the
suppression of the mTORC1 pathway. Using novel mice and molecular tools the proposed
work will test the hypothesis that PP2Ac represents a main contributor in the
immunopathogenesis of SLE and autoimmunity in general by 1) determining the importance of
PP2A expression in Tregs in the regulation of the autoimmune response and related pathology;
2) determining the importance of PP2A expression in conventional T cells in the regulation of
the autoimmune response and related pathology; and 3) establishing the aberrant expression of
the regulatory subunit Bα in human SLE and determine how it contributes to IL-17 production.
This project will generate novel concepts (differential regulation of central immune functions by
PP2A, regulation of distinct functions by specific regulatory subunits) and new informative mice
(mice lacking PP2A in T cell subsets and mice lacking regulatory subunits in T cells).
Understanding the molecular complexity which underlies the expression of systemic
autoimmunity is significant to the extent we wish to correct important pathways to treat patients.
The ability to carry out parallel studies in mice and humans increases significantly the
translational value of our work.
!
!
!
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
T cells in Lupus
-
批准号:10308697
-
项目类别:
-
资助金额:$43.75万
-
财政年份:2019
-
负责人:George C Tsokos
-
依托单位:
T cells in Lupus
-
批准号:10533282
-
项目类别:
-
资助金额:$43.75万
-
财政年份:2019
-
负责人:George C Tsokos
-
依托单位:
T cells in Lupus
-
批准号:10063477
-
项目类别:
-
资助金额:$43.75万
-
财政年份:2019
-
负责人:George C Tsokos
-
依托单位:
Phosphatases in Systemic Autoimmunity
-
批准号:10000837
-
项目类别:
-
资助金额:$43.75万
-
财政年份:2018
-
负责人:George C Tsokos
-
依托单位:
Phosphatases in Systemic Autoimmunity
-
批准号:10242137
-
项目类别:
-
资助金额:$43.75万
-
财政年份:2018
-
负责人:George C Tsokos
-
依托单位:
Targeting CaMK4 in SLE
-
批准号:9247888
-
项目类别:
-
资助金额:$35.94万
-
财政年份:2013
-
负责人:George C Tsokos
-
依托单位:
Targeting CaMK4 in SLE
-
批准号:8640886
-
项目类别:
-
资助金额:$36.03万
-
财政年份:2013
-
负责人:George C Tsokos
-
依托单位:
Targeting CaMK4 in SLE
-
批准号:8480535
-
项目类别:
-
资助金额:$37.62万
-
财政年份:2013
-
负责人:George C Tsokos
-
依托单位:
Targeting CaMK4 in SLE
-
批准号:9040093
-
项目类别:
-
资助金额:$35.97万
-
财政年份:2013
-
负责人:George C Tsokos
-
依托单位:
Expanded double negative T cells in SLE
-
批准号:8453448
-
项目类别:
-
资助金额:$40.48万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
Expanded double negative T cells in SLE
-
批准号:8653524
-
项目类别:
-
资助金额:$43.07万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
Expanded double negative T cells in SLE
-
批准号:7791807
-
项目类别:
-
资助金额:$43.45万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
Expanded double negative T cells in SLE
-
批准号:8066298
-
项目类别:
-
资助金额:$43.07万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
Expanded Double Negative T cells in SLE.
-
批准号:10620721
-
项目类别:
-
资助金额:$50.48万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
Expanded Double Negative T cells in SLE.
-
批准号:10295607
-
项目类别:
-
资助金额:$52.36万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
Expanded double negative T cells in SLE
-
批准号:8259759
-
项目类别:
-
资助金额:$43.07万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
Expanded Double Negative T cells in SLE.
-
批准号:10424576
-
项目类别:
-
资助金额:$50.48万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
CIS School in Systemic Autoimmune Diseases
-
批准号:7664206
-
项目类别:
-
资助金额:$1.75万
-
财政年份:2009
-
负责人:George C Tsokos
-
依托单位:
CIS School in Systemic Autoimmune Diseases
-
批准号:7800479
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2009
-
负责人:George C Tsokos
-
依托单位:
CIS School in Systemic Autoimmune Diseases
-
批准号:7484755
-
项目类别:
-
资助金额:$1.75万
-
财政年份:2008
-
负责人:George C Tsokos
-
依托单位:
国内基金
海外基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
-
批准号:31171277
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:Christine Nardini
-
依托单位: